Literature DB >> 6024192

Urinary metabolites in congenital hyperuricosuria.

M E Balis, I H Krakoff, P H Berman, J Dancis.   

Abstract

The excretion of oxypurine metabolites in urine of patients with congenital hyperuricosuria exceeds, on a creatinine basis, that observed in any previously recognized metabolic anomaly. The ratio of hypoxanthine to xanthine is from 2:1 to 3:1 and results from increased hypoxanthine excretion, in contrast to other hyperuricosuric conditions where ratios of less than one have been reported. Administration of allopurinol (a xanthine-oxidase inhibitor) reduces the excretion of uric acid but results in an equivalent increase in xanthine and hypoxanthine. These features appear to be unique to congenital hyper-uricosuria.

Entities:  

Mesh:

Substances:

Year:  1967        PMID: 6024192     DOI: 10.1126/science.156.3778.1122

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  10 in total

1.  Combined deficiency of xanthine oxidase and sulphite oxidase: a defect of molybdenum metabolism or transport?

Authors:  M Duran; F A Beemer; C van de Heiden; J Korteland; P K de Bree; M Brink; S K Wadman; I Lombeck
Journal:  J Inherit Metab Dis       Date:  1978       Impact factor: 4.982

2.  Inosinate pyrophosphorylase activity in immature blood cells in X-linked congenital hyperuricosuria.

Authors:  J Dancis; V Jansen; P H Berman; M E Balis
Journal:  Biochem Genet       Date:  1969-08       Impact factor: 1.890

3.  Hyperuricosuric encephalopathy without hyperuricaemia.

Authors:  C Hooft; C Van Nevel; A F De Schaepdryver
Journal:  Arch Dis Child       Date:  1968-12       Impact factor: 3.791

4.  Hyperuricaemia: some biochemical aspects.

Authors:  R W Watts
Journal:  Proc R Soc Med       Date:  1969-08

Review 5.  Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants.

Authors:  Rosa J Torres; Juan G Puig; H A Jinnah
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

6.  Combined xanthine and sulphite oxidase defect due to a deficiency of molybdenum cofactor.

Authors:  R A Roesel; F Bowyer; P R Blankenship; F A Hommes
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

Review 7.  Genotypic and phenotypic spectrum in attenuated variants of Lesch-Nyhan disease.

Authors:  Rong Fu; Chung-Jen Chen; H A Jinnah
Journal:  Mol Genet Metab       Date:  2014-05-28       Impact factor: 4.797

8.  Disparate enzyme activity in erythocytes and leukocytes. A variant of hypoxanthine phosphoribosyl-transferase deficiency with an unstable enzyme.

Authors:  J Dancis; L C Yip; R P Cox; S Piomelli; M E Balis
Journal:  J Clin Invest       Date:  1973-08       Impact factor: 14.808

9.  Purification of IMP:pyrophosphate phosphoribosyltransferases, catalytically incompetent enzymes in Lesch-Nyhan disease.

Authors:  C S Rubin; J Dancis; L C Yip; R C Nowinski; M E Balis
Journal:  Proc Natl Acad Sci U S A       Date:  1971-07       Impact factor: 11.205

10.  Study of purine metabolism in a xanthinuric female.

Authors:  M J Bradford; I H Krakoff; R Leeper; M E Balis
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.